• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by CalAmp Corp.

    7/22/22 4:15:29 PM ET
    $CAMP
    Get the next $CAMP alert in real time by email
    SC 13D 1 p22-1872sc13d.htm CALAMP CORP.

     

    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
    (Amendment No. __)*
     

    CalAmp Corp.

    (Name of Issuer)
     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    128126109

    (CUSIP Number)
     
    B. Riley Asset Management, LLC
    3811 Turtle Creek Boulevard, Suite 2100
    Dallas, TX 75219
     
    Eleazer Klein, Esq.
    Adriana Schwartz, Esq.
    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    July 12, 2022

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

     

    (Page 1 of 10 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 128126109

    SCHEDULE 13DPage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    B. Riley Asset Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY

    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    2,229,159

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    2,229,159

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,229,159

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.17%

    14

    TYPE OF REPORTING PERSON

    IA

             

     

     

     

    CUSIP No. 128126109

    SCHEDULE 13DPage 3 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Wes Cummins

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY

    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    2,229,159

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    2,229,159

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,229,159

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.17%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

    CUSIP No. 128126109

    SCHEDULE 13DPage 4 of 10 Pages

     

     

    Item 1. SECURITY AND ISSUER
       
      This statement on Schedule 13D (the "Schedule 13D") relates to the shares of common stock, par value $0.01 per share ("Shares"), of CalAmp Corp., a Delaware corporation (the "Issuer").  The Issuer's principal executive offices are located at 15635 Alton Parkway, Suite 250, Irvine, CA 92618.  

     

    Item 2. IDENTITY AND BACKGROUND
       
    (a) This Schedule 13D is being filed on behalf of (i) B. Riley Asset Management, LLC ("BRAM") with respect to the Shares held by certain funds and accounts (the "BRAM Funds and Accounts") to which it acts an investment manager and (ii) Wes Cummins ("Mr. Cummins" and, together with BRAM, the "Reporting Persons"), who is the President of BRAM.  
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
       
    (b) The principal business address of each of the Reporting Persons is 3811 Turtle Creek Boulevard, Suite 2100, Dallas, TX 75219.
       
    (c) The principal business of: (i) BRAM is to invest in securities and (ii) Mr. Cummins is to serve as the President of BRAM.
       
    (d)-(e) During the last five (5) years, none of the Reporting Persons has: (1) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (2) been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
       
    (f) BRAM is a Delaware limited liability company.  Mr. Cummins is a citizen of the United States of America.  

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
       
      Funds for the purchase of the Shares beneficially owned by the Reporting Persons reported herein were derived from general working capital of the BRAM Funds and Accounts.
       
      The Reporting Persons used a total of approximately $11,636,628, including brokerage commissions, in the aggregate to acquire the 2,229,159 Shares reported herein as beneficially owned by them.

     

     

    CUSIP No. 128126109

    SCHEDULE 13DPage 5 of 10 Pages

     

      The Reporting Persons have and may effect purchases of Shares through margin accounts maintained with prime brokers, which extend margin credit as and when required to open or carry positions in their margin accounts, subject to applicable federal margin regulations, stock exchange rules and such firms' credit policies.  Positions in the Shares may be held in margin accounts and may be pledged as collateral security for the repayment of debit balances in such accounts.

     

    Item 4. PURPOSE OF TRANSACTION
       
      Each of the Reporting Persons acquired the securities reported herein for investment purposes and because they believe the Shares are undervalued and represent an attractive investment opportunity.  
       
      On June 21, 2022, BRAM entered into a cooperation agreement with the Issuer (the "Cooperation Agreement") and issued a joint press release with the Issuer announcing the Cooperation Agreement and certain of its material terms.  Pursuant to the Cooperation Agreement, the Issuer appointed Mr. Cummins to the board of directors of the Issuer, effective immediately following the execution of the Cooperation Agreement, and agreed to include Mr. Cummins in the Issuer's slate of nominees for election as directors of the Issuer at the Issuer's 2022 annual meeting of stockholders.
       
      The foregoing description of the Cooperation Agreement is qualified in its entirety by reference to the full text of the Cooperation Agreement, which is attached as Exhibit 2 to this Schedule 13D and is incorporated by reference into this Item 4.
       
      Subject to the terms the Cooperation Agreement, the Reporting Persons have had and may continue to have discussions with officers and directors of the Issuer in connection with the Reporting Persons' investment in the Issuer.  The topics of these conversations may cover a range of issues, including those relating to the business of the Issuer, management, board composition, investor communications, operations, capital allocation, dividend policy, financial condition, mergers and acquisitions strategy, overall business strategy, executive compensation and corporate governance related to the Issuer's business and stakeholders.  The Reporting Persons may also have similar conversations with other stockholders or other interested parties, such as industry analysts, existing or potential strategic partners or competitors, investment professionals and other investors and may exchange information with any such persons or the Issuer pursuant to appropriate confidentiality or similar agreements (which may contain customary standstill provisions).  The Reporting Persons may at any time reconsider and change their intentions relating to the foregoing.  The Reporting Persons may also take one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D and may discuss or propose such actions with the Issuer's management and the board of directors of the Issuer, other stockholders of the Issuer, and other interested parties, such as those set out above.

     

     

     

    CUSIP No. 128126109

    SCHEDULE 13DPage 6 of 10 Pages

     

      Depending on various factors including, without limitation, the Issuer's financial position and strategic direction, the outcome of the discussions and actions referenced above, actions taken by the Issuer's board of directors, price levels of the Shares, liquidity requirements and other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, the Reporting Persons may in the future take actions with respect to their investment position in the Issuer as they deem appropriate including, without limitation, purchasing additional Shares or other instruments that are based upon or relate to the value of the Shares of the Issuer in the open market or otherwise, selling some or all of the securities reported herein, and/or engaging in hedging or similar transactions with respect to the Shares, except as may be limited by the Cooperation Agreement.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Shares and percentages of the Shares beneficially owned by the Reporting Persons.  The percentages used in this Schedule 13D are calculated based upon 36,157,466 Shares outstanding as of June 21, 2022, as reported in the Issuer's Quarterly Report for the quarterly period ended May 31, 2022 filed on Form 10-Q with the Securities and Exchange Commission on June 23, 2022.
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) Information concerning transactions in the Shares effected by the Reporting Persons during the past sixty (60) days is set forth in Annex A hereto and is incorporated herein by reference. All of the transactions in Shares listed hereto were effected in the open market through various brokerage entities.

     

    (d) No person other than the Reporting Persons and the BRAM Funds and Accounts are known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares held by the BRAM Funds and Accounts. 272 Capital Fund LP, a BRAM fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Shares.
       
    (e) Not applicable.

     

     

     

     

    CUSIP No. 128126109

    SCHEDULE 13DPage 7 of 10 Pages

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
       
     

    On June 21, 2022, the Issuer, BRAM and 272 Capital Master Fund Ltd. entered into the Cooperation Agreement. A copy of such agreement is included as Exhibit 2 to this Schedule 13D and is incorporated by reference herein.

     

    Except as otherwise described in this Schedule 13D and the joint filing agreement attached hereto as Exhibit 1, there are no contracts, arrangements, understandings or similar relationships with respect to the securities of the Issuer between the Reporting Persons and any other person or entity.

       
    Item 7. MATERIAL TO BE FILED AS EXHIBITS
       
    Exhibit 1: Joint Filing Agreement, dated July 22, 2022.
    Exhibit 2: Cooperation Agreement (incorporated by reference to Exhibit 99.1 of the Current Report on Form 8-K, filed by the Issuer with the Securities and Exchange Commission on June 22, 2022).

     

     

     

     

     

     

    CUSIP No. 128126109

    SCHEDULE 13DPage 8 of 10 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: July 22, 2022

     

     

    B. Riley Asset Management, LLC    
         
         
    /s/ Wes Cummins    
    Name: Wes Cummins    
    Title: President    

     

         
    /s/ Wes Cummins    
    WES CUMMINS    

     

     

     

     

     

    CUSIP No. 128126109

    SCHEDULE 13DPage 9 of 10 Pages

    EXHIBIT 1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate.

    DATE: July 22, 2022

     

     

    B. Riley Asset Management, LLC    
         
         
    /s/ Wes Cummins    
    Name: Wes Cummins    
    Title: President    

     

     

         
    /s/ Wes Cummins    
    WES CUMMINS    

     

     

     

     

     

    CUSIP No. 128126109

    SCHEDULE 13DPage 10 of 10 Pages

    Annex A

    Transactions in the Shares of the Issuer by the Reporting Persons During the Last Sixty (60) Days

    The following tables set forth all transactions in the Shares effected in the past sixty days by the Reporting Persons. Except as noted below, all such transactions were effected in the open market through brokers and the price per share includes commissions. Where a price range is provided in the column Price Range ($), the price reported in that row's Price Per Share ($) column is a weighted average price. These Shares were purchased in multiple transactions at prices between the price ranges indicated in the Price Range ($) column. The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of Shares purchased at each separate price.

     

     

     

     

    Trade Date Shares Purchased (Sold) Weighted Average Price Per Share ($) Price Range ($)
    7/14/2022 40,000 4.206400 4.11-4.25
    7/13/2022 107,587 4.081300 3.91-4.10
    7/12/2022 274,207 4.138240 3.98-4.18
    7/11/2022 100,000 4.119518 3.93-4.18
    6/30/2022 106,900 4.138253 4.02-4.21
    6/29/2022 120,000 4.306300 4.25-4.41
    6/28/2022 105,000 4.694396 4.62-4.82
    5/27/2022 20,787 7.148257 7.13-7.15
    5/25/2022 150,000 6.633040 6.00-6.90
    5/24/2022 55,403 6.358004 6.24-6.40
    5/23/2022 37,480 6.391923 6.35-6.40

     

    Get the next $CAMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAMP

    DatePrice TargetRatingAnalyst
    10/2/2025$7.00Overweight
    Cantor Fitzgerald
    9/16/2025Overweight → Neutral
    Analyst
    5/27/2025$8.00Outperform
    Wedbush
    11/5/2024Outperform
    William Blair
    11/5/2024$18.00Overweight
    Piper Sandler
    11/5/2024$23.00Overweight
    JP Morgan
    8/16/2022$8.00 → $10.00Hold → Buy
    Craig Hallum
    12/22/2021$15.00 → $14.00Buy
    Canaccord Genuity
    More analyst ratings

    $CAMP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CAMP4 Therapeutics Corporation

    SCHEDULE 13G/A - Camp4 Therapeutics Corp (0001736730) (Subject)

    2/5/26 1:20:38 PM ET
    $CAMP

    CAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

    1/9/26 4:32:35 PM ET
    $CAMP

    SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

    SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    1/8/26 12:15:25 PM ET
    $CAMP

    $CAMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on January 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the C

    1/16/26 4:05:00 PM ET
    $CAMP

    CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 14, 2026, at 3:45 p.m. PST. The event will be webcast and can be accessed on the investor relations page of CAMP4's website at

    1/6/26 8:00:00 AM ET
    $CAMP

    CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock

    CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of $6.00 per share. The gross proceeds to the Company from this offering are expected to be $30.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close

    12/18/25 7:10:00 AM ET
    $CAMP

    $CAMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on CAMP4 Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $7.00

    10/2/25 8:38:59 AM ET
    $CAMP

    CAMP4 Therapeutics downgraded by Analyst

    Analyst downgraded CAMP4 Therapeutics from Overweight to Neutral

    9/16/25 8:02:50 AM ET
    $CAMP

    Wedbush initiated coverage on CAMP4 Therapeutics with a new price target

    Wedbush initiated coverage of CAMP4 Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/27/25 9:09:57 AM ET
    $CAMP

    $CAMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Tardiff Daniel

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    12/22/25 5:42:07 PM ET
    $CAMP

    SEC Form 4 filed by Chief Medical Officer Maricich Yuri

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    12/22/25 5:41:49 PM ET
    $CAMP

    SEC Form 4 filed by Chief Financial Officer Gold Kelly

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    12/22/25 5:41:33 PM ET
    $CAMP

    $CAMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner 5am Partners Vi, Llc bought $4,499,999 worth of shares (2,941,176 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/15/25 8:12:20 PM ET
    $CAMP

    Large owner Polaris Management Co. Vii, L.L.C. bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:59:09 PM ET
    $CAMP

    Director Nashat Amir bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:48:30 PM ET
    $CAMP

    $CAMP
    Leadership Updates

    Live Leadership Updates

    View All

    Sequans Appoints Jason W. Cohenour to Board of Directors

    Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra

    6/30/25 8:00:00 AM ET
    $CAMP
    $LTRX
    $RFIL
    Computer Communications Equipment
    Telecommunications
    Electrical Products
    Technology

    CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

    With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

    3/18/25 8:00:00 AM ET
    $CAMP

    CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    12/10/24 8:00:00 AM ET
    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 6:49:57 PM ET
    $CAMP

    SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

    SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 5:50:56 PM ET
    $CAMP

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 4:19:08 PM ET
    $CAMP

    $CAMP
    Financials

    Live finance-specific insights

    View All

    CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

    IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

    1/9/24 4:30:00 PM ET
    $CAMP

    CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

    IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

    12/26/23 4:30:00 PM ET
    $CAMP

    CalAmp Announces Completion of Strategic Financing with Lynrock Lake

    IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

    12/18/23 4:31:00 PM ET
    $CAMP